Jewish Family Services launches new disability services program

In the continued effort to help individuals and families face life’s daily challenges, Jewish Family Services now offers a program to meet the needs of people with intellectual/developmental disabilities . The goal of the new JFS Disability Services program is to support the quality of life and independence of people with I/DD.

Is My Dog or Cat a Healthy Weight? Important Questions to Ask the Vet

Your 8-year-old chocolate lab is putting on weight, and you know she should probably lose a pound or two. But when she looks at you pleadingly with those big brown eyes, how can you resist handing out just one more treat? “Just as obesity has become a serious problem in people, it’s also a growing problem in pets, one that can seriously harm your pet’s health,” says Carmela Stamper, a veterinarian in the Center for Veterinary Medicine at the U.S. Food and Drug Administration .

ACA Repeal

… al coverage limit and the amount the government pays for “catastrophic” drug coverage. (3) Rewarding reimbursement to health plans, doctors and other medical care providers if they improve health outcomes and quality.

Next 25 Articles

In a speech to a joint session of Congress Tuesday night, President Donald Trump outlined five principles to guide lawmakers when repealing and replacing the Affordable Care Act. “Tonight I am also calling on this Congress to repeal and replace Obamacare with reforms that expand choice, increase access, lower cost, and at the same time provide better health care,” the president said.

No Smoking Day 2017- be proud to be a quitter

Mid Ulster District Council in partnership with the Public Health Agency are encouraging smokers in the area to quit smoking on this day and ‘Be Proud to be a Quitter’. The annual No Smoking Day is a perfect opportunity for smokers to get motivated to quit smoking, particularly if their new years’ resolutions have been broken or are in need of renewing.

FDA OKs Merck’s allergen extract to treat house dust mite-induced allergic rhinitis

The FDA approves Merck’s Odactra, the first allergen extract that is administered sublingually to treat house dust mite-induced nasal inflammation , with or without eye inflammation in people between the ages of 18 and 65. Odactra, a once-daily tablet that rapidly dissolves under the tongue, exposes patients to house dust mite allergens with the aim of gradually training the immune system to reduce the frequency and severity of nasal and eye allergy symptoms. It is taken year-round.

Cleveland Clinic opening new cancer center

The new Cleveland Clinic Taussig Cancer Center will welcome patients March 6. The 377,000-square-foot facility, shown above, will house all outpatient cancer treatment services in one location, with the center’s medical and radiation oncologists, surgeons, nurses, genetic counselors, social workers and others working in one shared space to improve patient outcomes.

Ditch the paracetamol and try ACUPUNCTURE

Ditch the paracetamol and try ACUPUNCTURE: Scientists prove it can rewire the brain and make the body better able to cope with pain It is caused by a nerve in the wrist being squeezed and subsequently alters an area of the brain related to touch, scientists claim. But the new study found the ancient Chinese practice rewires the brain and helps to combat the aching and tingling sensations.

New Research from Peter Millett, MD, MSc on the Positive Effects of…

The comprehensive arthroscopic management procedure has been shown to improve shoulder arthritis symptoms and increase patient satisfaction postoperatively in young, active patients. “We now have a minimally-invasive joint preserving procedure that can reliably help young, active patients suffering from glenohumeral osteoarthritis,” said Dr. Millett.

Aequus Licenses Rights to Cannabinoid Transdermal Patch to Treat Neurological Disorders

Aequus has been focused on expanding treatment options for neurological disorders through its current pipeline of development stage and in-licensed products. Aequus recognizes there has been an increased acceptance around the use of cannabinoids for epilepsy and MS in particular, however, uptake by the medical community has been limited by a need for a product that provides precise, controlled dose delivery.

Recro Pharma to Present at Upcoming Investor Conferences

MALVERN, Pa., March 02, 2017 — Recro Pharma, Inc. , a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings, currently developing non-opioid products for the treatment of serious acute pain, today announced that Gerri Henwood, the Companys President and Chief Executive Officer, will present at the following upcoming investor conferences: The Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 11:20 am ET at the Boston Marriott Copley Place.   The 29th Annual ROTH Conference on Tuesday, March 14, 2017 at 2:30 pm PT at the Ritz Carlton Laguna Niguel in Dana Point.

Advaxis to Host Research Reception at Society of Gynecologic Oncology …

Advaxis, Inc. , a clinical-stage biotechnology company developing cancer immunotherapies, will host a Research Reception during the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. The reception will be held from 5:30-7:00 p.m. ET on Monday, March 13, in National Harbor Room 15 at the Gaylord Convention Center in National Harbor, MD.

Melinta Therapeutics and Menarini Group Enter into Commercial and…

Melinta Therapeutics , a privately held company developing novel antibiotics to treat serious bacterial infections, and Menarini Group, an Italian biopharmaceutical group, today announced the signing of a development and commercialization agreement. As part of this agreement, Melinta has granted the Menarini Group exclusive rights to commercialize Delafloxacin , an investigational anionic fluoroquinolone, under their own brands in 68 countries in Europe, Asia-Pacific including China, South Korea, and Australia , and the Commonwealth of Independent States including Russia.

BIOPHYTIS: Full results of SARA-PK study confirm Sarconeos’ good…

BIOPHYTIS , a biotechnology company specializing in the development of drug candidates to treat diseases of ageing, announces today the complete results of the SARA-PK study, in particular the favorable pharmacokinetics and pharmacodynamics of Sarconeos. The analyses confirm the good pharmacokinetic profile in healthy elderly volunteers, the therapeutic window of Sarconeos, and confirms the dosages that will be tested in the Phase 2b trial SARA-INT.

Great War. Small, Bracing, Shows

That’s an idea, but not the only one, that emerges from two small exhibitions that Yale University is mounting to mark the centennial of the War to End All Wars. “Yale Medicine Goes to War, 1917” and “Refugees, Immigration, and Library Books for Soldiers: A Selection of World War I Posters” are on view in the corridor and in the rotunda of the John Hay Whitney Medical Library over on Cedar Street at the medical campus.

Emma McCloskey is celebrating two years clear after battling a tumour the size of a newborn baby.

A YOUNG woman who was given a five per cent chance of survival after she was diagnosed with a tumour the size of a newborn baby is celebrating a new lease of life after being given the all-clear. Emma McCloskey was diagnosed with sarcoma, an rare and aggressive soft tissue cancer, four-and-a-half years ago after doctors discovered that she had a tumour weighing nearly eight pounds wrapped around her right leg.

European shares steady, strong results boost Melrose and Subsea

European shares steadied early on Thursday, pausing after a strong rally in the previous session, with strong earnings updates driving shares in Melrose Industries and Subsea 7. The pan-European STOXX 600 index was flat in percentage terms by 0826 GMT. Basic resources stocks were again the top gainers, up 1 percent, after a more than 2.9 percent rise on Wednesday.

UPDATE 1-Roche says drug combo cuts breast cancer deaths in key trial

Combining Roche’s Perjeta and Herceptin drugs with chemotherapy reduced recurrence of aggressive breast cancer or death compared to Herceptin and chemo, the Swiss drugmaker said on Thursday. “These results from the positive Aphinity study represent an important addition to the body of data for Perjeta in the treatment of people with HER2-positive early breast cancer,” Sandra Horning, Roche’s chief medical officer, said.

Associated Press

Allowing insurers to market health care policies across state lines is one of President Donald Trump’s main ideas for bringing down costs. While supporters of the idea cast it as a way to make insurance policies more competitive, critics say it’s unlikely to result in more affordable plans and could undermine stronger consumer protections in states such as California and Hawaii.

Desk jobs increase risk of heart disease

… seven to eight miles, or spending seven hours per day upright. “Our findings could be used as the basis of new public health targets for sitting, lying, standing and stepping to avoid metabolic risks. Participants in the study wore a tiny physical …